---
title: Amivantamab plus Lazertinib in Previously Untreated <em>EGFR</em>-Mutated Advanced
  NSCLC
date: '2024-06-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38924756/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240627181917&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Amivantamab-lazertinib showed superior efficacy to osimertinib
  as first-line treatment in EGFR-mutated advanced NSCLC. (Funded by Janssen Research
  and Development; MARIPOSA ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Amivantamab-lazertinib showed superior efficacy to osimertinib as first-line treatment in EGFR-mutated advanced NSCLC. (Funded by Janssen Research and Development; MARIPOSA ClinicalTrials.gov number, ...